Skip to search boxSkip to navigationSkip to main content

Nek1 phosphorylates von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization

  • Mallikarjun Patil
    ,
  • Navjotsingh Pabla
    ,
  • Shuang Huang
    ,
  • Zheng Dong(corresponding author)
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

Loss of function in either VHL or Nek1 leads to cyst formation in tissues, especially in kidneys. Whether there is a connection between pVHL and Nek1 regulation is unknown. Here, we report that the VHL protein (pVHL) may be a substrate of Nek1. While Nek1 can phosphorylate pVHL at multiple sites, the phosphorylation at serine-168 results in pVHL degradation. Nek1-mediated phosphorylation of pVHL does not significantly affect hypoxia-inducible factors (HIF), a known target of pVHL. However, non-phosphorylable pVHL reconstituted in VHL-deficient cells induces more stable cilia than wild-type VHL during serum stimulation and Nocodazole treatment. The results suggest a possible regulation of pVHL by Nek1 that may contribute to ciliary homeostasis and cystogenesis.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 166-171 (6 pages)

Journal (Volume, Issue Number)

Cell Cycle (Volume 12, Issue 1)

Publication milestones

  • Published - 01/01/2013

Publication status

Published - 01/01/2013

ISSN

1538-4101

Publication IDs

  • Scopus: 84872324536
  • PubMed: 23255108

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
0.55
SciVal
Author count
4
SciVal
citations
14
SciVal
Paper percentile
73
Fractional count
2
Fractional count
0.50
Fractional count
2
Fractional count
0.50
Fractional count
2
Fractional count
1

PlumX, opens in new tab

Captures
43
Citation count
18

Funding Details

We thank Dr. William Kaelin at Harvard Medical School for providing the HA-VHL-pRc-CMV plasmid and Dr. Celeste Simon at University of Pennsylvania for RCC4 cells. The study was supported in part by research grants from the National Institutes of Health and Department of Veteran’s Affairs.